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s the Decision Final?*
effrey Brinker, MD
altimore, Maryland
y its nature percutaneous coronary intervention (PCI)
reates a pro-thrombotic environment that would be pro-
ibitive in the absence of effective antithrombotic therapy.
he risk of an ischemic adverse event is further increased
hen there is pre-existent platelet activation and clot, such
s with acute coronary syndromes (ACS), and in the
resence of a stent. Antithrombotic therapy, however, has
ts own risks that are increased in the setting of invasive
ascular procedures. The challenge for PCI has been to
alance the risk of ischemic complication against that of
leeding. The fear of the former has traditionally granted it
rimacy, motivating ever more aggressive antithrombotic
egimens until evidence that benefit, in terms of preventing
schemic events, plateaued (1–3). The evolution of anti-
hrombotic pharmacotherapy as an adjunct to PCI has as its
ornerstone unfractionated heparin to which aspirin, dipy-
idamole, low molecular weight dextran, warfarin, thienopy-
idines, and glycoprotein IIb/IIIa receptor inhibitors (GPIs)
ave at one time or another been added. Bleeding, the
bvious risk of such strategy, has traditionally been consid-
red a necessary evil, almost always “manageable” and thus
f secondary concern. Current data, however, have demon-
trated that major bleeding complicating PCI is more than
ust a nuisance; it is undeniably associated with an increased
isk of death (4–8).
See page 2556
A major stimulus for rethinking the bleeding risk associ-
ted with PCI has come from industry-supported clinical
nvestigations of newer antithrombotic agents, most notably
he direct thrombin inhibitor bivalirudin, as alternatives or
djuncts to heparin. The first major trial comparing biva-
irudin with heparin monotherapy in patients with unstable
ngina, published 15 years ago (9,10), showed that bleeding,
ransfusion, and the composite ischemic end point were all
ecreased by the former. It was implied that bleeding be
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thef
merican College of Cardiology.
From the Division of Cardiology, Johns Hopkins Hospital, Baltimore, Maryland.onsidered a major adverse cardiac event (MACE) equiva-
ent, a concept revisited later as an expanded net adverse
oronary event and having recent support (6). Subsequent
tudies, in progressively high-risk patients, comparing biva-
irudin with heparin plus GPI (the evolved standard) un-
quivocally demonstrated decreased bleeding with the
ormer (11–14) without a significant increase in ischemic
vents. Although these results seem to invalidate the axiom
f an inverse relationship between antithrombotic safety and
fficacy, there have been signals (e.g., numerically increased
schemic events in the REPLACE [Randomized Evalu-
tion in PCI Linking Angiomax to Reduced Clinical
vents]-2 [12] and ACUITY [Acute Catheterization and
rgent Intervention Triage Strategy] [13] trials, and
reater incidence of very early stent thrombosis in the
ORIZONS-AMI [Harmonizing Outcomes with Revascu-
arization and Stents in Acute Myocardial Infarction] trial
14]) that suggest caution in accepting this interpretation (15).
In this issue of the Journal, Mehran et al. (16) combine
he formidable ACUITY (13,17) and HORIZONS-AMI
atasets (14,18) to further explore the risk of major bleeding
nd its implications. A newly-derived bleeding risk score
ncorporates 6 baseline factors (of which only the white
lood cell count is novel) and 1 modifiable parameter, the
ntithrombotic regimen. The accuracy of risk prediction
ith this construct is improved over the authors’ former
odel (19) and equivalent to others (20,21). Most of the
dentified risk factors for bleeding were also found to be
ndependent predictors of mortality, with the notable ex-
eption of antithrombotic regimen. Patients could, on the
asis of the score, be sorted into groups of increasing risk of
leeding that correlated with observed events. Bivalirudin
ecreased bleeding below that expected across all of the
roups, having a larger absolute benefit as risk increased.
he investigators also confirmed previous observations
22,23) that PCI-related myocardial infarction and major
leeding have similar influence on 1-year mortality and that
he risk posed by the former is limited to 30 days after the
vent, whereas that of the latter extends beyond this time
rame, suggesting a more sustained burden associated with a
ajor bleed. The addition of the ACUITY data to that of
ORIZONS-AMI might seem justified, assuming similar
athophysiology, but the former study—despite a 47%
elative reduction in major bleeding—failed to demonstrate
reduction in 1-year mortality with bivalirudin mono-
herapy either in the overall population or in high-risk (e.g.,
iomarker-positive) subgroups (17). Thus, although evi-
ence from the large and well-designed trials comparing
ivalirudin with heparin-GPI establishes a decreased bleed-
ng risk associated with the former, in only the ST-segment
levation myocardial infarction population can that benefit
e clearly related to a decrease in mortality. The disconnect
etween reduced bleeding and absence of mortality reduc-
ion in other populations remains disturbing and requires
urther study.
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The Score Is In June 8, 2010:2567–9Although peri-PCI bleeding has been associated with an
ncrease in myocardial infarction and stroke (24), the
inkage between bleeding and death remains unclear. Be-
ause many of the risk factors for bleeding are also inde-
endent predictors of mortality, it is possible that these
dverse events are linked only by a common risk factor
pedigree” (25,26), although this view is not widely ac-
epted. Although massive bleeding or even limited bleeding
nto a crucial area (e.g., intracerebral) can directly lead to
eath, these events are relatively uncommon. Mortality does
eem to be related to the extent of bleeding, but even minor
leeding carries with it some risk suggesting a “dose-effect”
elationship (23). Recent attention has been focused on
nflammatory, pro-coagulant, and other mechanisms as
ediating the adverse outcomes accompanying bleeding
nd transfusion (27). Reduced antiplatelet therapy in the
ace of bleeding is also important in PCI and might underlie
he absence of increased mortality in bypass patients expe-
iencing major bleeding (16). Regardless of the mechanisms
nvolved, bleeding is an undesirable event in terms of early
nd delayed outcome, and efforts to decrease its incidence
nd optimize its management should be pursued.
Mehran et al. (16) have shown that bivalirudin is an
ffective strategy to reduce bleeding risk; however, there are
ther modifiable components of PCI that also might be
ssociated with bleeding and deserve attention. It has been
uggested, for instance, that GPI might be omitted in
eparin-treated patients receiving aggressive thienopyridine
osing (28,29). Perhaps the greatest opportunity to reduce
leeding and its sequelae, however, is a procedural rather
han pharmacologic parameter. Marked reductions in bleed-
ng have been reported when PCI is performed from radial
s opposed to femoral arterial access without a sacrifice in
rocedural success or increase in ischemic complications
5,30). Radial access might allow for more aggressive
djunctive antithrombotic therapy as well (31). It would
eem important that—accepting bleeding as an ominous
redictor of morbidity and mortality—radial artery access
or PCI become more widely adopted and used whenever
easible to reduce access site complications including major
leeding. Although we have been taught much from the
ivalirudin trials, there is considerably more to learn about
CI technique and adjunctive pharmacotherapy before its
afety and effectiveness can be optimized. We know the
core, but the game is not over.
ddress for correspondence and reprint requests: Dr. Jeffrey
rinker, Division of Cardiology, Johns Hopkins Hospital, CMSC
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